Literature DB >> 33158956

Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity.

Lan Luo1,2, Yuhong Chen1, Xiao Chen3, Yongwei Zheng1, Vivian Zhou3, Mei Yu1, Robert Burns1, Wen Zhu1,4, Guoping Fu1, Juan C Felix5, Christopher Hartley5, Alisa Damnernsawad6, Jing Zhang6, Renren Wen1, Williams R Drobyski3, Chunji Gao2, Demin Wang7,4.   

Abstract

Acute graft-versus-host disease (aGVHD) is one major serious complication that is induced by alloreactive donor T cells recognizing host Ags and limits the success of allogeneic hematopoietic stem cell transplantation. In the current studies, we identified a critical role of Kras in regulating alloreactive T cell function during aGVHD. Kras deletion in donor T cells dramatically reduced aGVHD mortality and severity in an MHC-mismatched allogeneic hematopoietic stem cell transplantation mouse model but largely maintained the antitumor capacity. Kras-deficient CD4 and CD8 T cells exhibited impaired TCR-induced activation of the ERK pathway. Kras deficiency altered TCR-induced gene expression profiles, including the reduced expression of various inflammatory cytokines and chemokines. Moreover, Kras deficiency inhibited IL-6-mediated Th17 cell differentiation and impaired IL-6-induced ERK activation and gene expression in CD4 T cells. These findings support Kras as a novel and effective therapeutic target for aGVHD.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33158956      PMCID: PMC7955895          DOI: 10.4049/jimmunol.2000006

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  GTP-dependent segregation of H-ras from lipid rafts is required for biological activity.

Authors:  I A Prior; A Harding; J Yan; J Sluimer; R G Parton; J F Hancock
Journal:  Nat Cell Biol       Date:  2001-04       Impact factor: 28.824

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

Authors:  Isao Tawara; Motoko Koyama; Chen Liu; Tomomi Toubai; Dafydd Thomas; Rebecca Evers; Peter Chockley; Evelyn Nieves; Yaping Sun; Kathleen P Lowler; Chelsea Malter; Norihiro Nishimoto; Geoffrey R Hill; Pavan Reddy
Journal:  Clin Cancer Res       Date:  2010-11-03       Impact factor: 12.531

Review 4.  Differentiation of effector CD4 T cell populations (*).

Authors:  Jinfang Zhu; Hidehiro Yamane; William E Paul
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

Authors:  K R Cooke; L Kobzik; T R Martin; J Brewer; J Delmonte; J M Crawford; J L Ferrara
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

6.  Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1.

Authors:  X F Zhang; J Settleman; J M Kyriakis; E Takeuchi-Suzuki; S J Elledge; M S Marshall; J T Bruder; U R Rapp; J Avruch
Journal:  Nature       Date:  1993-07-22       Impact factor: 49.962

Review 7.  AP-1 as a regulator of cell life and death.

Authors:  Eitan Shaulian; Michael Karin
Journal:  Nat Cell Biol       Date:  2002-05       Impact factor: 28.824

8.  Integration of MAP kinase signal transduction pathways at the serum response element.

Authors:  A J Whitmarsh; P Shore; A D Sharrocks; R J Davis
Journal:  Science       Date:  1995-07-21       Impact factor: 47.728

Review 9.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

10.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

View more
  2 in total

1.  Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.

Authors:  Zhi Wen; Grant Yun; Alexander Hebert; Guangyao Kong; Erik A Ranheim; Remington Finn; Adhithi Rajagoplan; Shuyi Li; Yun Zhou; Mei Yu; Alisa Damnernsawad; Jeroen P Roose; Joshua J Coon; Renren Wen; Demin Wang; Jing Zhang
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

2.  Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.

Authors:  Evan Flietner; Zhi Wen; Adhithi Rajagopalan; Oisun Jung; Lyndsay Watkins; Joshua Wiesner; Xiaona You; Yun Zhou; Yuqian Sun; Brock Kingstad-Bakke; Natalie S Callander; Alan Rapraeger; M Suresh; Fotis Asimakopoulos; Jing Zhang
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.